ID   HS-Sch-2
AC   CVCL_8718
SY   HS-sch-2; HSSCH2
DR   CLO; CLO_0050146
DR   BCRJ; 0376
DR   BioSample; SAMN03472028
DR   cancercelllines; CVCL_8718
DR   DepMap; ACH-002066
DR   IARC_TP53; 17934
DR   RCB; RCB2230
DR   Wikidata; Q54896291
RX   PubMed=10891546;
RX   PubMed=28556483;
RX   PubMed=32642732;
RX   PubMed=33707600;
RX   PubMed=34059954;
RX   PubMed=36818284;
CC   Problematic cell line: Misclassified. Originally thought to be a malignant peripheral nerve sheath tumor (MPNST) but shown to be from a desmplastic melanoma (PubMed=36818284). This is based on a number of criteria such as the result of a methylome-based classifier, the expression of the SOX10 and S100B markers, a WT status for PRC2 genes, the complete inactivation of NF1 and CDKN2A and negative staining for Melan-A.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~56 hours (PubMed=10891546).
CC   Karyotypic information: Average ploidy of 3.89 (PubMed=36818284).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous; Note=By translocation (PubMed=34059954).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Glu91Asnfs*6 (c.270_288del); Zygosity=Heterozygous; Note=Somatic (PubMed=36818284).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; c.3113+1G>A; ClinVar=VCV000000345; Zygosity=Heterozygous; Note=Splice donor mutation. Somatic (PubMed=36818284).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=10891546; DepMap=ACH-002066).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Peripheral nervous system, left sciatic nerve; UBERON=UBERON_0001322.
ST   Source(s): PubMed=28556483; PubMed=33707600; PubMed=36818284; RCB=RCB2230
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 13 (PubMed=33707600)
ST   D18S51: 13,14 (PubMed=28556483; PubMed=36818284)
ST   D19S433: 10.2,14.2 (PubMed=33707600)
ST   D19S433: 14.2 (PubMed=28556483; PubMed=36818284)
ST   D21S11: 29,30
ST   D2S1338: 20
ST   D3S1358: 18
ST   D5S818: 13
ST   D7S820: 8,11 (PubMed=28556483; PubMed=36818284; RCB=RCB2230)
ST   D7S820: 11 (PubMed=33707600)
ST   D8S1179: 14
ST   FGA: 23,26
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C37257; Desmoplastic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 27
//
RX   PubMed=10891546; DOI=10.3892/ijo.17.2.347;
RA   Sonobe H., Takeuchi T., Furihata M., Taguchi T., Kawai A., Ohjimi Y.,
RA   Iwasaki H., Kaneko Y., Ohtsuki Y.;
RT   "A new human malignant peripheral nerve sheath tumour-cell line, HS-Sch-2,
RT   harbouring p53 point mutation.";
RL   Int. J. Oncol. 17:347-352(2000).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086; PMCID=PMC5579334;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:i50-i61(2020).
//
RX   PubMed=33707600; DOI=10.1038/s41598-021-85055-2; PMCID=PMC7952412;
RA   Longo J.F., Brosius S.N., Znoyko I., Alers V.A., Jenkins D.P.,
RA   Wilson R.C., Carroll A.J. 3rd, Wolff D.J., Roth K.A., Carroll S.L.;
RT   "Establishment and genomic characterization of a sporadic malignant
RT   peripheral nerve sheath tumor cell line.";
RL   Sci. Rep. 11:5690.1-5690.19(2021).
//
RX   PubMed=34059954; DOI=10.1007/s00439-021-02296-x;
RA   Magallon-Lorenz M., Fernandez-Rodriguez J., Terribas E.,
RA   Creus-Bachiller E., Romagosa C., Estival A., Perez Sidelnikova D.,
RA   Salvador H., Villanueva A., Blanco I., Carrio M., Lazaro C., Serra E.,
RA   Gel B.;
RT   "Chromosomal translocations inactivating CDKN2A support a single path
RT   for malignant peripheral nerve sheath tumor initiation.";
RL   Hum. Genet. 140:1241-1252(2021).
//
RX   PubMed=36818284; DOI=10.1016/j.isci.2023.106096; PMCID=PMC9929861;
RA   Magallon-Lorenz M., Terribas E., Ortega-Bertran S., Creus-Bachiller E.,
RA   Fernandez M., Requena G., Rosas I., Mazuelas H., Uriarte-Arrazola I.,
RA   Negro A., Lausova T., Castellanos E., Blanco I., DeVries G.H.,
RA   Kawashima H., Legius E., Brems H., Mautner V.-F., Kluwe L., Ratner N.,
RA   Wallace M.R., Fernandez-Rodriguez J., Lazaro C., Fletcher J.A.,
RA   Reuss D.E., Carrio M., Gel B., Serra E.;
RT   "Deep genomic analysis of malignant peripheral nerve sheath tumor cell
RT   lines challenges current malignant peripheral nerve sheath tumor
RT   diagnosis.";
RL   iScience 26:106096.1-106096.22(2023).
//